Susmed

Susmed Net Margin

The Net Profit Margin of Susmed (4263.T) as of Oct 28, 2026 is -76.97 %. In the previous year, Net Profit Margin was -64.45 % — a change of 19.42% (lower).

Net Margin

-76.97 %

YoY

19.42%

Last updated:

Net Profit Margin of Susmed is 2026 -76.97 % . Net Profit Margin of Susmed was 2025 -64.45 % . It decreases by 19.42% lower compared to the previous year.

For Susmed, the net margin of -77.0% is down versus -73.7% a few years ago.

The Susmed Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2020
-277.81 JPY
Jan 1, 2021
-240.33 JPY
Jan 1, 2022
-73.68 JPY
Jan 1, 2023
-9.56 JPY
Jan 1, 2024
-104.33 JPY
Jan 1, 2025
-64.45 JPY
Jan 1, 2026
-76.97 JPY
The Susmed Net Margin history
YEARNet MarginYoY
-76.97 %+19.42%
-64.45 %-38.22%
-104.33 %+990.93%
-9.56 %-87.02%
-73.68 %-69.34%
-240.33 %-13.49%
-277.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Susmed Stock analysis

What does Susmed do? SUSMED, Inc. generates revenue through its DTx Product segment, which develops application software for treating insomnia, breast cancer, and chronic kidney diseases. The DTx Platform segment provides clinical trial systems, machine learning analysis systems, and DTx development support services. The company's primary customers are healthcare providers and pharmaceutical companies seeking digital therapeutics solutions. SUSMED targets the healthcare technology market with its specialized software and support services for disease treatment and clinical research. The DTx Product segment focuses on creating therapeutic applications for specific medical conditions, while the DTx Platform segment offers infrastructure for clinical trials and machine learning analysis. SUSMED's business model relies on selling both its proprietary software products and platform services to healthcare institutions and pharmaceutical firms. The company's revenue streams include software licensing, system subscriptions, and development support fees. SUSMED's products are designed to address chronic conditions like insomnia and breast cancer, with additional focus on chronic kidney diseases. The DTx Platform serves as a comprehensive solution for clinical trial management and machine learning-driven analysis, supporting pharmaceutical companies in their drug development processes. The company's services are tailored to meet the needs of healthcare technology providers and pharmaceutical developers. Susmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Susmed stock

Net Profit Margin of Susmed is -76.97 % in 2026.

Net Profit Margin of Susmed changed from -64.45 % to -76.97 %, representing a 19.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Susmed since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Susmed with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Susmed

All Key Metrics — Susmed